Oklahoma Senate Bill SB1033

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25

Caption

Practice of pharmacy; requiring licensure of certain out-of-state pharmacies; requiring certain inspections; providing administrative remedies and penalties. Effective date.

Impact

This legislation aims to enhance the regulation of pharmacy practices across state lines, ensuring that all pharmacies operating within Oklahoma's jurisdiction comply with the same standards as in-state pharmacies. By imposing licensure requirements and inspection protocols, SB1033 seeks to protect consumer safety and maintain the integrity of pharmaceutical practices. The measure also establishes a framework for annual inspections, which ensures continual compliance with the outlined regulations, thus improving oversight in a sector where safety and regulatory adherence are critical.

Summary

Senate Bill 1033 is a proposed legislation focused on the practice of pharmacy within Oklahoma. It requires that any pharmacy located outside the state that ships medications into Oklahoma must be licenced by the State Board of Pharmacy. The bill intends to enforce strict compliance with the state's pharmacy laws and incorporates specific provisions regarding the operational standards for these pharmacies, including adherence to prescribed pharmacy technician-to-pharmacist ratios and their storage and delivery methodologies. Violations of these mandates may lead to significant administrative penalties, including fines reaching up to $50,000.

Contention

Although the bill has been introduced with the intention of safeguarding public health, it may face contention regarding the operational impacts on out-of-state pharmacies. Critics may argue that such requirements could create barriers to service availability for residents relying on medications shipped from other states. Additionally, there are potential concerns about the financial burden that compliance with annual inspections and potential fines could place on pharmacies, particularly smaller or independent operations. Balancing regulatory oversight while ensuring access to medications remains a crucial point of discussion.